Ivermectin for COVID-19: From Pandemic Controversy to Definitive Futility in the REMAP-CAP and Global Randomized Trials

The REMAP-CAP trial found no clinical benefit for ivermectin in improving organ support-free days or hospital survival in critically or non-critically ill patients.
Large-scale meta-analyses involving over 23,000 participants confirm that ivermectin does not reduce all-cause mortality in either hospitalized or outpatient settings.
Evidence from major platform trials like PRINCIPLE and ACTIV-6 demonstrates that ivermectin is unlikely to provide clinically meaningful improvements in recovery time or prevent hospitalization.
International clinical guidelines now strongly discourage ivermectin use, citing a lack of high-quality evidence despite its widespread political and public distribution early in the pandemic.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The REMAP-CAP trial found no clinical benefit for ivermectin in improving organ support-free days or hospital survival in critically or non-critically ill patients.
Large-scale meta-analyses involving over 23,000 participants confirm that ivermectin does not reduce all-cause mortality in either hospitalized or outpatient settings.
Evidence from major platform trials like PRINCIPLE and ACTIV-6 demonstrates that ivermectin is unlikely to provide clinically meaningful improvements in recovery time or prevent hospitalization.
International clinical guidelines now strongly discourage ivermectin use, citing a lack of high-quality evidence despite its widespread political and public distribution early in the pandemic.

Sign in free to continue reading